Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Portfolio Pulse from
Myriad Genetics has announced the integration of its proprietary HRD platform into Illumina's updated gene panel assay, TruSight™ Oncology 500 v2. This collaboration enhances the capabilities of Illumina's assay in oncology diagnostics.
November 20, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Illumina's TruSight™ Oncology 500 v2 now includes Myriad Genetics' HRD platform, potentially enhancing its assay's capabilities and appeal in the oncology diagnostics market.
The inclusion of Myriad's HRD platform in Illumina's assay could make the TruSight™ Oncology 500 v2 more comprehensive and appealing to users, potentially increasing its adoption and sales.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Myriad Genetics' HRD platform is now integrated into Illumina's TruSight™ Oncology 500 v2, potentially increasing its market reach and credibility in oncology diagnostics.
The integration of Myriad's HRD platform into a widely used assay like Illumina's TruSight™ Oncology 500 v2 could enhance Myriad's market presence and credibility in the oncology diagnostics field, potentially leading to increased demand for its platform.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80